KRAS and colorectal carcinoma: In this cohort of stage II CRC patients, the authors found that combining the BRAF mutation status with KRAS and PIK3CA mutational status increased the sensitivity in predicting PFS and OS compared to the BRAF mutation alone (ROC AUC 0.65 p < 0.002 vs. ROC AUC 0.54 p = 0.392) [81].